Comparison of pretransplantation characteristics between MRDneg and MRDpos patients
| . | MRDneg (n = 199) . | MRDpos (n = 54) . | P* . |
|---|---|---|---|
| Median age at HCT (range), y | 42.5 (0.6-71.6) | 47.6 (2.2-72.6) | NS |
| Male gender, n (%) | 95 (47.7%) | 36 (66.7%) | .014 |
| Median WBC at diagnosis, ×103/µL | 11.6 (0.2-297) | 5.3 (0.3-326) | NS |
| Cytogenetics, n (%)* | .040 | ||
| Favorable | 20 (10.1%) | 2 (3.7%) | |
| Intermediate | 137 (68.8%) | 31 (57.4%) | |
| Adverse | 37 (18.6%) | 19 (35.2%) | |
| Missing | 5 (2.5%) | 2 (3.7%) | |
| Secondary AML, n (%) | 46 (23.1%) | 23 (42.6%) | 0.004 |
| No. of induction courses, n (%) | NS | ||
| 1 | 136 (68.3%) | 31 (57.4%) | |
| 2 | 56 (28.1%) | 19 (35.2%) | |
| ≥3 | 7 (3.5%) | 4 (7.4%) | |
| Consolidation therapy after initial induction, n (%) | <.001 | ||
| No | 23 (11.6%) | 17 (31.5%) | |
| Yes | 176 (88.4%) | 37 (68.5%) | |
| No. of consolidation courses | .009 | ||
| 1 | 92 (46.2%) | 19 (35.2%) | |
| ≥2 | 84 (42.2%) | 18 (33.3%) | |
| No. of re-induction courses, n (%) | NS | ||
| 1 | 41 (20.1%) | 16 (29.6%) | |
| 2 | 8 (4.0%) | 2 (3.7%) | |
| ≥3 | 3 (1.5%) | 0 (0%) | |
| Consolidation therapy after re-induction, n (%) | NS | ||
| No | 32 (16.1%) | 14 (25.9%) | |
| Yes | 20 (10.1%) | 4 (7.4%) | |
| No. of consolidation courses | NS | ||
| 1 | 18 (9.1%) | 4 (7.4%) | |
| ≥2 | 2 (1.0%) | 0 (0%) | |
| Median remission duration before HCT (range), d | |||
| For CR1 patients | 127 (18-465) | 93 (16-383) | .015 |
| For CR2 patients | 59.5 (17-231) | 54 (17-203) | NS |
| Peripheral blood counts before HCT | .006 | ||
| ANC ≥1000/µL and platelets ≥100 000/µL | 176 (88.4%) | 40 (74.1%) | |
| ANC <1000/µL and/or platelets <100 000/µL | 22 (11.1%) | 14 (25.9%) | |
| Missing | 1 (0.5%) | 0 (0%) | |
| Routine cytogenetics before HCT, n (%) | <.001 | ||
| Normal karyotype | 183 (92.0%) | 39 (72.2%) | |
| Abnormal karyotype | 11 (5.5%) | 13 (24.1%) | |
| Missing/inadequate data | 5 (2.5%) | 2 (3.7%) | |
| CR status, n (%) | NS | ||
| CR1 | 147 (73.9%) | 36 (66.7%) | |
| CR2 | 52 (26.1%) | 18 (33.3%) |
| . | MRDneg (n = 199) . | MRDpos (n = 54) . | P* . |
|---|---|---|---|
| Median age at HCT (range), y | 42.5 (0.6-71.6) | 47.6 (2.2-72.6) | NS |
| Male gender, n (%) | 95 (47.7%) | 36 (66.7%) | .014 |
| Median WBC at diagnosis, ×103/µL | 11.6 (0.2-297) | 5.3 (0.3-326) | NS |
| Cytogenetics, n (%)* | .040 | ||
| Favorable | 20 (10.1%) | 2 (3.7%) | |
| Intermediate | 137 (68.8%) | 31 (57.4%) | |
| Adverse | 37 (18.6%) | 19 (35.2%) | |
| Missing | 5 (2.5%) | 2 (3.7%) | |
| Secondary AML, n (%) | 46 (23.1%) | 23 (42.6%) | 0.004 |
| No. of induction courses, n (%) | NS | ||
| 1 | 136 (68.3%) | 31 (57.4%) | |
| 2 | 56 (28.1%) | 19 (35.2%) | |
| ≥3 | 7 (3.5%) | 4 (7.4%) | |
| Consolidation therapy after initial induction, n (%) | <.001 | ||
| No | 23 (11.6%) | 17 (31.5%) | |
| Yes | 176 (88.4%) | 37 (68.5%) | |
| No. of consolidation courses | .009 | ||
| 1 | 92 (46.2%) | 19 (35.2%) | |
| ≥2 | 84 (42.2%) | 18 (33.3%) | |
| No. of re-induction courses, n (%) | NS | ||
| 1 | 41 (20.1%) | 16 (29.6%) | |
| 2 | 8 (4.0%) | 2 (3.7%) | |
| ≥3 | 3 (1.5%) | 0 (0%) | |
| Consolidation therapy after re-induction, n (%) | NS | ||
| No | 32 (16.1%) | 14 (25.9%) | |
| Yes | 20 (10.1%) | 4 (7.4%) | |
| No. of consolidation courses | NS | ||
| 1 | 18 (9.1%) | 4 (7.4%) | |
| ≥2 | 2 (1.0%) | 0 (0%) | |
| Median remission duration before HCT (range), d | |||
| For CR1 patients | 127 (18-465) | 93 (16-383) | .015 |
| For CR2 patients | 59.5 (17-231) | 54 (17-203) | NS |
| Peripheral blood counts before HCT | .006 | ||
| ANC ≥1000/µL and platelets ≥100 000/µL | 176 (88.4%) | 40 (74.1%) | |
| ANC <1000/µL and/or platelets <100 000/µL | 22 (11.1%) | 14 (25.9%) | |
| Missing | 1 (0.5%) | 0 (0%) | |
| Routine cytogenetics before HCT, n (%) | <.001 | ||
| Normal karyotype | 183 (92.0%) | 39 (72.2%) | |
| Abnormal karyotype | 11 (5.5%) | 13 (24.1%) | |
| Missing/inadequate data | 5 (2.5%) | 2 (3.7%) | |
| CR status, n (%) | NS | ||
| CR1 | 147 (73.9%) | 36 (66.7%) | |
| CR2 | 52 (26.1%) | 18 (33.3%) |
ANC, absolute neutrophil count; NS, not significant; WBC, white blood cell count.
For the comparison MRDneg vs MRDpos.